Home › NDC Lookup › Ingredients › Erythromycin › 70244-0031-02
Erythromycin 5 mg/g Ointment, 1 tube — NDC 70244-0031-02 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Erythromycin 5 mg/g Ointment, 1 tube — NDC 70244-031-02 (Billing 70244-0031-02)

by Sentiss Pharmaceuticals LLC · 1 TUBE in 1 CARTON / 3.5 g in 1 TUBE

This is a package of 1 tube of Erythromycin 5 mg/g Ointment from Sentiss Pharmaceuticals LLC, marketed since Apr 2026 and currently FDA-listed; retail pharmacies pay about $2.83 per g (NADAC).

NDC 70244-0031-02
🏷️ FDA NDC (as labeled) 70244-031-02 billing pads the product segment with a zero
This package
Contains1 tube Cost per g$2.83 NADAC Per package$9.89 / 3.5 g Pack sizes2 compare ↓
Also priced by: Part D plans $3.24/unit — full pricing hub ↓
Product page 70244-0031-01 Also comes in: 50 tubes 70244-031-01
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Erythromycin (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Apr 29, 2026 — CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0545-2026
Class II · Apr 29, 2026 — CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0544-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70244-031-02
Product NDC 70244-031
11-digit billing NDC 70244003102
NCPDP billing unit GM — per gram (weight)
RxCUI 310149
UNII 63937KV33D
Application # ANDA064030
SPL Set ID 4da0e351-383f-55da-e063-6394a90a8eba
Established class (EPC) Macrolide; Macrolide Antimicrobial
Physiologic effect Decreased Sebaceous Gland Activity
Chemical class Macrolides
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2026-04-01
Route OPHTHALMIC
Dosage form OINTMENT
Substance ERYTHROMYCIN
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 86101025004210
GCN Seq No 007948
GCN 33540
HICL code 004022
Ingredient (HICL) Erythromycin Base
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6W
Therapeutic class — specific (HIC3) Ophthalmic Antibiotics
AHFS code 08:12.12.04
AHFS class Erythromycin Antibiotics
FDB label name ERYTHROMYCIN 0.5% EYE OINTMENT
FDB brand name Erythromycin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007948
  • GCN: 33540
  • GPI-14 (Medi-Span): 86101025004210
  • HICL (First Databank): 004022
  • AHFS class code: 08:12.12.04
  • RxCUI (RxNorm): 310149
Why two NDCs? The FDA registers this code as 70244-031-02 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 70244-0031-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Macrolide class.

Pharmacologic class Macrolide, Macrolide Antimicrobial
Drug family (ATC) Antiinfectives for treatment of acne, Macrolides, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ERYTHROMYCIN 0.5% EYE OINTMENT Ingredient Erythromycin Base
📗 Our plain-language guide HelloPharmacist
  • It treats minor bacterial infections on the surface of the eye, affecting the conjunctiva and/or cornea. It's also used in newborns to help prevent eye infections from gonorrhea or...
  • For an eye infection, you apply a ribbon of ointment about 1 cm long directly to the infected area. Depending on how severe it is, this can be done up to 6 times a day. Follow your...
  • No. The ointment should stay in the eye and not be flushed out after you apply it. Your vision may feel a bit different for a moment, but that's not a reason to rinse it away.
  • Should I rinse it out after putting it in?
📖 Read our full Erythromycin Ophthalmic guide →
7
Nutrient depletion considerations

Erythromycin may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Erythromycin nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $2.827 $9.89 / 3.5 g
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $3.24 $11.34 / 3.5 g
NADAC price history (per g) — tap or hover for the price & month
Aug 2026 Sep 2026 $2.834 $2.827
Flat over the last 2 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
70244-0031-01 70244-031-01 Main listing 50 TUBE in 1 CARTON / 1 g in 1 TUBE $6.83 / g $341.70 2026-04-01 — Active
70244-0031-02 You're viewing this 1 TUBE in 1 CARTON / 3.5 g in 1 TUBE $2.83 / g $9.89 2026-04-01 — Active

This pack has the lowest per-g cost of the 2 priced pack sizes ($2.83 NADAC).

Pack size FAQ

What quantity is in this package?
This package contains 1 tube — 1 tube in 1 carton / 3.5 g in 1 tube.
How does this package differ from NDC 70244-0031-01?
Both are Erythromycin 5 mg/g Ointment — the drug itself is identical. This page's package is the 1 tube one, while NDC 70244-0031-01 is the 50 tubes package. Per-g NADAC also differs: $2.83 here vs $6.83 for the 50 tubes pack.
What NDC number is used to bill for this package of Erythromycin 5 mg/g Ointment?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Erythromycin 5 mg/gthis 70244-0031-02 Sentiss 1 tube $2.827 AT Availability likely —
Erythromycin 5 mg/g 24208-0910-19 Bausch 50 tubes $6.834 AT Availability likely +142%
Erythromycin 5 mg/g 72485-0670-31 ARMAS 50 tubes $6.834 AT Availability likely +142%
Erythromycin 5 mg/g 48102-0057-11 Fera 50 tubes — — FDA listed —
Erythromycin 5 mg/g 50090-1484-00 A-S 1 tube — AT FDA listed —
erythromycin 5 mg/g 50090-1958-00 A-S 1 tube — — FDA listed —
Erythromycin 5 mg/g 55154-7850-00 Cardinal 10 tubes — AT FDA listed —
Erythromycin 5 mg/g 60760-0670-35 ST. 1 tube — AT FDA listed —
Erythromycin 5 mg/g 61919-0090-35 Direct 3.5 g — AT FDA listed —
Erythromycin 5 mg/g 63187-0267-35 Proficient 1 tube — AT FDA listed —
Erythromycin 5 mg/g 63187-0608-35 Proficient 1 tube — AT FDA listed —
Erythromycin 5 mg/g 66267-0975-35 NuCare 3.5 g — AT FDA listed —
Erythromycin 5 mg/g 67296-2128-03 Redpharm 1 tube — AT FDA listed —
Erythromycin 5 mg/g 68071-3992-02 NuCare 1 tube — AT FDA listed —
Erythromycin 5 mg/g 68071-4228-03 NuCare 3.5 g — AT FDA listed —
erythromycin 5 mg/g 68071-4803-03 NuCare 3.5 g — — FDA listed —
Erythromycin 5 mg/g 68788-9328-03 Preferred 1 tube — AT FDA listed —
Erythromycin 5 mg/g 70518-0465-00 REMEDYREPACK 1 tube — AT FDA listed —
Erythromycin 5 mg/g 76420-0196-03 Asclemed 1 tube — AT FDA listed —
Erythromycin 5 mg/g 76420-0212-30 Asclemed 1 tube — AT FDA listed —
erythromycin 5 mg/g 76420-0612-03 Asclemed 1 tube — — FDA listed —
Erythromycin 5 mg/g 85766-0248-55 Sportpharm 1 tube — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2026
On the market since
Apr 2026
📍
2026
Currently FDA-listed
listed with the FDA
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII T5L8T28FGP
    Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
  • UNII 4T6H12BN9U
    Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.

2 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerSentiss Pharmaceuticals LLC
Application holderSENTISS AG
FDA applicationANDA064030 (ANDA)
Labeler code70244
First marketedApr 2026
Product typeHuman Prescription Drug
Portfolio7 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 97 words ▾

INDICATIONS AND USAGE: For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.gonorrhoeae is not established.

For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.

⏱️ Dosage and Administration 86 words ▾

DOSAGE AND ADMINISTRATION: In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of Erythromycin Opthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation.

A new tube should be used for each infant.

⛔ Contraindications 14 words ▾

CONTRAINDICATIONS: This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

🤒 Adverse Reactions 31 words ▾

ADVERSE REACTIONS: The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions. To report SUSPECTED ADVERSE REACTIONS, contact Sentiss at 1-855-473-6847 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

🤰 Pregnancy 86 words ▾

Pregnancy: Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. No evidence of harm to the fetus that appeared related to erythromycin was reported in these studies.

There are, however, no adequate and well controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.

🧒 Pediatric Use 12 words ▾

Pediatric Use - See INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION .

🧓 Geriatric Use 17 words ▾

Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.

🧬 Clinical Pharmacology 79 words ▾

CLINICAL PHARMACOLOGY: Microbiology: Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitro and in clinical infections: Streptococcus pyogenes (group A β-hemolytic) Alpha-hemolytic streptococci (viridans group) Staphylococcus aureus , including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin) Streptococcus pneumoniae Mycoplasma pneumoniae (Eaton Agent, PPLO) Haemophilus influenzae (not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved) Treponema pallidum Corynebacterium diphtheriae Neisseria gonorrhoeae Chlamydia trachomatis

📦 How Supplied / Storage and Handling 79 words ▾

HOW SUPPLIED: Sterile Erythromycin Ophthalmic Ointment USP, 0.5% is available as follows: 3.5 g (1/8 oz) sterile tamper-resistant tube (NDC 70244-031-02) Carton of fifty (50) Unit Dose 1 g tube (NDC 70244-031-01) STORAGE: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing.

Distributed by: Sentiss Pharmaceuticals, LLC.. San Clemente, CA 92672 Manufactured by: Ophtapharm AG, Riethofstrasse 1, Hellingen, 8442, Switzerland (CHE) for Sentiss Made in Switzerland 83081200 Rev. 03/26

📦 Storage and Handling 47 words ▾

STORAGE: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing. Distributed by: Sentiss Pharmaceuticals, LLC.. San Clemente, CA 92672 Manufactured by: Ophtapharm AG, Riethofstrasse 1, Hellingen, 8442, Switzerland (CHE) for Sentiss Made in Switzerland 83081200 Rev. 03/26

📋 Description 99 words ▾

DESCRIPTION: Erythromycin Ophthalmic Ointment belongs to the macrolide group of antibiotics. It is basic and readily forms a salt when combined with an acid. The base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform.

Erythromycin ((3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-dideoxy-3-C-methyl-3- O -methyl-α-L- ribo -hexopyranosyl)-oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethyl-amino)-β-D- xylo -hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione)) is an antibiotic produced from a strain of Streptomyces erythraeus. It has the following structural formula: Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base of mineral oil and white petrolatum. Structural Formula

💬 Information for Patients 17 words ▾

Information for Patients: Avoid contaminating the applicator tip with material from the eye, fingers, or other source.

⚠️ Precautions 218 words ▾

PRECAUTIONS: General: The use of antimicrobial agents may be associated with the overgrowth of nonsusceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken. Information for Patients: Avoid contaminating the applicator tip with material from the eye, fingers, or other source. Carcinogenesis, Mutagenesis, Impairment of Fertility: Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity.

Mutagenicity studies have not been conducted. No evidence of impaired fertility that appeared related to erythromycin was reported in animal studies. Pregnancy: Teratogenic Effects: Pregnancy Category B.

Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. No evidence of harm to the fetus that appeared related to erythromycin was reported in these studies. There are, however, no adequate and well controlled studies in pregnant women.

Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed. Nursing Mothers: Caution should be exercised when erythromycin is administered to a nursing woman. Pediatric Use - See INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION .

Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.

🍼 Nursing Mothers 14 words ▾

Nursing Mothers: Caution should be exercised when erythromycin is administered to a nursing woman.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 41 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility: Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted. No evidence of impaired fertility that appeared related to erythromycin was reported in animal studies.

📄 Package Label / Principal Display Panel 88 words ▾

Principal Display Panel Text for Container Label NDC 70244-031-02 ERYTHROMYCIN OPHTHALMIC OINTMENT USP, 0.5% Rx only Sterile Net Wt. 3.5 g (1/8 oz.) NDC 70244-031-01 ERYTHROMYCIN OPHTHALMIC OINTMENT USP, 0.5% Rx only Sterile Net Wt. 1 g 02 label Container label 01

Principal Display Panel Text for Carton Label 3.5 g NDC 70244-031-02 ERYTHROMYCIN OPHTHALMIC OINTMENT USP, 0.5% Rx only Sterile Net Wt 3.5 g (1/8 oz.) 1 g NDC 70244-031-01 ERYTHROMYCIN OPHTHALMIC OINTMENT USP, 0.5% Rx only Sterile Net Wt 1 g 02 container container label 01

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Erythromycin — the program that covers self-administered drugs. 12 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Erythromycin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$6.84M
Claims incl. refills
399.1K
Beneficiaries
329.3K
Spend / beneficiary
$20.78
Spend / claim
$17.15
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Erythromycin — the ingredient across all brands.

Top reported reactions

Drug Hypersensitivity4,159
Nausea1,319
Vomiting1,157
Diarrhoea1,112
Dyspnoea1,076
Fatigue1,066
Rash1,046

Age at onset

Neonate107
Infant49
Child100
Adolescent64
Adult1,399
Elderly1,168

Reporter sex

19,105 reports
Male · 30%
Female · 70%
Unknown · 0%

Serious outcomes

Hospitalization5,067
Death1,712
Life-threatening1,327
Disabling1,168
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,844 379
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 70242-0133-05 · Dannso 70244-0033-01 · Sentiss →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.